| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3996925 | Practical Radiation Oncology | 2014 | 6 Pages |
Abstract
Prostate-specific antigen decline during SRT may be a valuable prognostic factor for subsequent clinical outcomes. Future studies should investigate the value of monitoring PSA during SRT and how PSA response may be used to personalize therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Rafi MD, Nitin MD, Raquibul MD, PhD, Nima BS, Sujith MD, Kevin P. MS, Waleed F. MD, Reza MD, Shalom MD, Chandan MD, PhD, Madhur K. MD,